BROADCASTS.com

The number of people in the U.S. confirmed to be infected with the pandemic-level respiratory coronavirus continues to rise, even as testing and diagnosis capacity continues to lag behind other nations. In the meantime, epidemiologists are urging people all over the country to take actions that help “flatten the curve,” to slow the rate of infection so the number of cases don’t overwhelm the healthcare system and make the virus even more dangerous for those who get it.

And the best methods to flatten that curve? Social distancing, which means limiting your exposure to other people, including large gatherings. And, when you can’t avoid other people, it means washing your hands diligently, disinfecting door knobs, and otherwise killing virus particles—which may survive up to three days on inanimate objects, depending on conditions.

There are words we use every day for common things or ideas—meme, vaccine, dinosaur—but where did those words come from? Sometimes, there’s a scientific backstory.

Take the word quarantine, now in the news due to widespread infection control measures. Did you know that it comes from quarantino, a 40-day isolation period for arriving ships—which originally was a trentino, a 30-day period, established in what is now Croatia in the plague-stricken 1340’s?

Science Friday’s word nerd Johanna Mayer joins Ira to talk about the origins of the word quarantine, and how she flips through science history and culture to tell us these stories in her new podcast Science Diction.

The first season of Science Diction is now available! Listen and subscribe wherever you enjoy your podcasts.

In 2012, the FDA approved the drug Truvada, the brand-name HIV pre-exposure prophylaxis (PrEP) that HIV negative people can take to prevent contracting the virus. The patent for Truvada is due to expire, which would allow for more generic versions of the drug. But Gilead, the manufacturer of Truvada, is releasing a second brand name PrEP called Descovy.  

Physician Rochelle Walensky, who is chief of the infectious disease division at Massachusetts General Hospital, is an author on a study in the Annals of Internal Medicine that weighed the financial and accessibility impact that this new drug will have for patients.